Gabriel K, Heinzerling L, von Baumgarten L, Subklewe M, Kobold S. The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy. Biochim Biophys Acta Mol Cell Res. 2026 Jan 23;1873(3):120115. doi: 10.1016/j.bbamcr.2026.120115. Epub ahead of print. PMID: 41581566.

Rotter SC, Arroyo-Araujo M, Drude NI, Pellegrini P, Kobold S, Richter GHS, Müller OJ, Bruder D, Riecken LB, Gerlach B, Schuler L, Salbach-Hirsch J, Dalloul I, Kühn S, Wilcke JC, Toelch U. Strengthening translational preclinical research through confirmatory multi-laboratory studies. Front Med (Lausanne). 2026 Jan 7;12:1715361. doi: 10.3389/fmed.2025.1715361. PMID: 41574368; PMCID: PMC12819244.

Michaelides S, Hartmann V, Nüssler V, Zielinski C, von Bergwelt-Baildon M, Kobold S. 11th Immunotherapy of Cancer conference (ITOC): A meeting report. Hum Vaccin Immunother. 2025 Dec;21(1):2532967. doi: 10.1080/21645515.2025.2532967. Epub 2025 Jul 18. PMID: 40679247; PMCID: PMC12279264.

Tigu AB, Nistor M, Gulei D, Constantinescu CS, Kegyes D, Cenariu D, Muresan X, Munteanu R, Feder R, Jitaru C, Bancos A, Santa M, Tomai R, Damian M, Ivancuta A, Rus I, Bojan A, Zdrenghea M, Buzoianu AD, Tanase A, Einsele H, Kobold S, Tomuleasa C.: CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases. Blood Rev. 2025 Nov 26:101354. doi: 10.1016/j.blre.2025.101354. Epub ahead of print. PMID: 41318274.JIF 5.7

Kobold S, Müller R. Aktuelle Fortschritte und neue Therapieoptionen in der Immunonkologie [Current progress and latest therapeutic options in immuno-oncology]. Dtsch Med Wochenschr. 2025 Nov;150(22):1335-1340. German. doi: 10.1055/a-2502-1305. Epub 2025 Oct 28. PMID: 41151612. JIF 0.6

Gabriel K, Kobold S. Long-term consequences of cancer therapy: cognitive impairment following CAR T cell therapy. Signal Transduct Target Ther. 2025 Jul 10;10(1):226. doi: 10.1038/s41392-025-02324-6. PMID: 40640140; PMCID: PMC12246034.

Trefny MP, Kroemer G, Zitvogel L, Kobold S. Metabolites as agents and targets for cancer immunotherapy. Nat Rev Drug Discov. 2025 Jun 26. doi: 10.1038/s41573-025-01227-z. Epub ahead of print. PMID: 40571788. JIF 101.8

Hoffmann GV, Gottschlich A, Subklewe M, Kobold S. Novel approaches to CAR T cell target identification in acute myeloid leukemia. Curr Opin Pharmacol. 2025 Apr 8;82:102524.

Schwarzlmueller P, Triebig A, Assié G, Jouinot A, Theurich S, Maier T, Beuschlein F, Kobold S, Kroiss M. Steroid hormones as modulators of anti-tumoural immunity. Nat Rev Endocrinol. 2025; 21, 331-343. doi: 10.1038/s41574-025-01102-22025. JIF 47,6

Nguyen NTT, Müller R, Briukhovetska D, Weber J, Feucht J, Künkele A, Hudecek M, Kobold S.
The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity.
Cancers 2024; 16(14): 2608. 
JIF²⁰²³ 4.5

Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K, Kobold S.
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.
BioDrugs 2024; 38(5): 611-637. 
JIF²⁰²³ 5.4

Kobold S.
Giving T-cell bispecifics a helping hand.
Blood 2024; 143:2115-2116. 
JIF²⁰²² 22.1

https://pubmed.ncbi.nlm.nih.gov/38780922/

Tsiverioti CA, Gottschlich A, Theurich S, Anders HJ, Kroiss M, Kobold S, Trefny M.
Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.  
Biological Chemistry 2024; 405:485-515.
JIF²⁰²² 3.7

https://pubmed.ncbi.nlm.nih.gov/38766710/

Trefny MP, Kobold S.
CAR T cells for solid tumors - developments to watch in 2023.
Expert Opinion on Biological Therapy 2024; 24:207-211.
JIF²⁰²² 5.5

https://pubmed.ncbi.nlm.nih.gov/38526025/

Becker M, Dirschl S, Scherm M, Serr I, Daniel C.
Niche-specific control of tissue function by regulatory T cells—Current challenges and perspectives for targeting metabolic disease.
Cell Metabolism 2024; 36:229-239.
JIF²⁰²² 29.0

https://www.sciencedirect.com/science/article/pii/S1550413123004709?via%3Dihub

Stock S, Klüver AK, Fertig L, Menkhoff VD, Subklewe M, Endres S, Kobold S.
Mechanisms and strategies for safe CAR T cell activity control.
International Journal of Cancer 2023, 153:1706-1725.
JIF²⁰²² 7.3

https://onlinelibrary.wiley.com/doi/10.1002/ijc.34635

Andreu-Sanz D, Kobold S.
Role and potential of different T helper cell subsets in adoptive cell therapy.
Cancers 2023, 15:1650.
JIF 5.2

https://pubmed.ncbi.nlm.nih.gov/36980536/

Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W, Grimminger F, Savai R.
Utility and drawbacks of chimeric antigen receptor T Cell (CAR-T) therapy in lung cancer.
Frontiers in Immunology 2022; 13:903562.
JIF 8.8

https://pubmed.ncbi.nlm.nih.gov/35720364/

Dalloul I, Strzalkowski T, von Bergwelt-Baildon M, Nüssler V, Zielinski Ch, Kobold S.
9th Immunotherapy of cancer conference (ITOC): a meeting report.
Human Vaccines & Immunotherapeutics 2022; 18:2159706.
JIF 4.5

https://pubmed.ncbi.nlm.nih.gov/36576266/

Michaelides S, Obeck H, Kechur D, Endres S, Kobold S.
Migratory engineering of T cells for cancer therapy.
Vaccines 2022, 10:1845.
JIF 5.0

https://pubmed.ncbi.nlm.nih.gov/36366354/

Tartour E, Mabrouk N, Tran T, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E.
CXCR6 expressing T cells: functions and role in the control of tumors.
Frontiers in Immunology 2022, 13:1022136.
JIF 8.8

https://pubmed.ncbi.nlm.nih.gov/36311728/

Märkl F, Huynh D, Endres S, Kobold S.
Utilizing chemokines in cancer immunotherapy.
Trends in Cancer 2022; 8:670-682.
JIF 14.2

https://pubmed.ncbi.nlm.nih.gov/35501268/

Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Böck S.
Novel systemic treatment approaches for metastatic pancreatic cancer.
Expert Opinion On Investigational Drugs 2022; 31:249-262.
JIF 6.2

https://pubmed.ncbi.nlm.nih.gov/35114868/

Umut Ö, Gottschlich A, Endres S, Kobold S.
CAR T cell therapy in solid tumors: a short review.
Magazine of European Medical Oncology 2021; 14:143-149.
JIF 1.0

Dezfouli A, Yazdi M, Pockley A, Khosravi M, Kobold S, Wagner E, Multhoff G.
NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development.
Cells 2021; 10:3390.
JIF 6.7

Briukhovetska D, Doerr J, Endres S, Libby P, Dinarello Ch, Kobold S.
Interleukins in cancer: from biology to therapy.
Nature Reviews Cancer 2021; 21:481-499.
JIF 53.0
https://www.nature.com/articles/s41568-021-00363-z
https://www.lmu-klinikum.de/aktuelles/pressemitteilungen/mit-interleukinen-gegen-den-krebs/94565a179b3a2184

Schwerdtfeger M, Desiderio V, Kobold S, Regad T, Zappavigna S, Caraglia M.
Long non-coding RNAs in cancer stem cells.
Translational Oncology 2021; 16:218-233.
JIF 4.1

Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S.
Chimeric antigen receptor–modified T cells and T cell–engaging bispecific antibodies: different tools for the same job.
Current Hematologic Malignancy Reports 2021; 16:218-233.

JIF 2.5
https://doi.org/10.1007/s11899-021-00628-2

Kobold S.
An in sitro assay to predict primary resistance to PD-1 blockade.
Trends in Molecular Medicine 2021; 27:297-298.
JIF 11.1
https://www.sciencedirect.com/science/article/pii/S147149142100037X?dgcid=author

Gottschlich A, Endres S, Kobold S.
Therapeutic strategies for targeting IL-1 in cancer.
Cancers 2021; 13:477.
JIF 6.1
https://www.mdpi.com/2072-6694/13/3/477/pdf

Koenig L, Boehmer D, Metzger P, Schnurr M, Endres S, Rothenfusser S.
Blocking inflammation on the way: rationale for CXCR2 antagonists for the treatment of COVID-19.
Journal of Experimental Medicine 2020; 217:e20201342.
JIF 10.9 

Lesch S, Benmebarek MR, Cadilha B, Stoiber S, Subklewe M, Endres S, Kobold S.
Determinants of response and resistance to CAR T cell therapy.
Seminars in Cancer Biology 2019; 65:80-90.
JIF 9.7 

Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
6th Immunotherapy of cancer conference (ITOC): advances and perspectives, a meeting report.
Journal for ImmunoTherapy of Cancer 2019; 8:e000268.
JIF 8.7

Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
6th Immunotherapy of cancer conference (ITOC): advances and perspectives, a meeting report.
Journal for ImmunoTherapy of Cancer 2019; 8:e000268.

JIF 8.7

Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K.
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Radiation Oncology 2019; 14:141.
JIF 2.9 

Kruger S, Ilmer M, Kobold S, Cadilha B, Endres S, Ormanns S, Schuebbe G, Renz W, D´Haese J, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
Advances in cancer immunotherapy 2019 – latest trends.
Journal of Experimental and Clinical Research 2019; 38:268.
JIF 6.2

Stoiber S, Cadilha B, Benmebarek MR, Lesch S, Endres S, Kobold S.
Limitations in the design of chimeric antigen receptors for cancer therapy.
Cells 2019; 8:E472:1-26
JIF 7.6

Darowski D, Kobold S, Jost C, Klein C.

Combining the best of two worlds: Highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Monoclonal Antibodies 2019; 20:1-11
JIF 5.2
https://doi.org/10.1080/19420862.2019.1596511

Benmebarek MR, Karches C, Cadilha B, Lesch S, Endres S, Kobold S*.
Killing mechanisms of chimeric antigen receptor (CAR) T cells.
International Journal of Molecular Sciences 2019; 20:1283.
JIF 3.7
https://www.ncbi.nlm.nih.gov/pubmed/?term=Benmebarek+MR

Kobold S.
Innate and adaptive immunity combined for cancer treatment. (comment)
Proceedings of the National Academy of Sciences USA 2019, 116:1087-1088
JIF 9.5

Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S.
Teaching an old dog new tricks: next generation CAR T cells.
British Journal of Cancer 2019; 120:26-37
JIF 6.2

Duewell P, Endres S, Kobold S.
Innate immune stimulation in cancer therapy.
Hematology/Oncology Clinics of North America 2018; 33:215-231.
JIF 3.1

Kobold S, Pantelyushin S, Rataj F, vom Berg J.
Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy.
Frontiers Oncology 2018; 9:1955
JIF 2.0

Kobold S, Krackhardt A, Schlösser H, Wolf D.
Immuno-Oncology: A Brief Overview
Deutsche Medizinische Wochenschrift 2018, 143:1006-1013.
JIF 0.6

Markota A, Endres S, Kobold S.
Targeting interleukin-22 for cancer therapy.
Human Vaccines & Immunotherapeutics 2018; 14:2012-2015
JIF 2.2

Rataj F, Endres S, Kobold S.
When the inhibitor is turned into stimulator: novel aspects in T cell engineering.
Translational Cancer Research 2018
JIF 1.8

Kobold S.
Komplexe Biosimilars in der Onkologie. Rituximab, Trastuzumab & co.
TZM News 2017; Ausgabe 4

Bauer C, Kuehnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M.
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Letters 2016; 391:259-68.
JIF 6,0
http://dx.doi.org/10.1016/j.canlet.2016.02.057

Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapie von Tumoren. Aktivierte T-Zellen als gemeinsame Endstrecke neu zugelassener Therapien.
Deutsches Ärzteblatt International 2015; 112:809-15
JIF 3,6
http://www.aerzteblatt.de/treffer?mode=x&wo=16&typ=16&aid=173073&s=Kobold

Immunotherapy in tumors. Activated T cells as a new treatment modality.
Deutsches Ärzteblatt International 2015; 112:809-15
JIF 3,6
http://www.ncbi.nlm.nih.gov/pubmed/26667979

Endres S, Meuer S, Scriba PC.
Klinische Immunintervention: aktuelle und künftige Ansätze
Arzneimittelforschung 2012; Volume 62.

Hotz C, Bourquin C.
Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything.
Oncoimmunology 2012; 1:227-228.

Bourquin C, Voelkl A, Endres S.
Toll-like receptor-7 ligands for the tumor therapy.
Arzneimittel-Forschung Drug Research 2006; 16

Dugas M, Weinzierl S, Pecar A, Endres S, Hasford J.
Design and implementation of a common drug information database for a university hospital.
Pharmacy World Science 2003; 25:156-161

Endres S, Hartmann G.
Therapeutische Oligonukleotide.
Deutsches Ärzteblatt 2003; 47:2577-82

Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G.
Recent advances in immunostimulatory CpG-oligonucleotides.
Current Opinions in Microbiology 2003; 5

Eigler A, Eigenbrod S, Endres S.
Medikamentös induzierte Pankreatitis.
Deutsche Medizinische Wochenschrift 2003; 128:1-4

Rothenfusser S, Tuma E, Endres S, Hartmann G.

Plamacytoid dendritic cells: The key to CpG.
Human Immunology 2002; 63:1111-9

Endres S, Buchardi C, Angstwurm M.
Diagnosespektrum in einer internistischen Notaufnahme.
Der Internist 2001; 42:1462-4

Kirchgeorg M, Endres S.
Patienten suchen und finden Gesundheitsinformationen im Internet.
Hessisches Ärzteblatt 2001; 9:437-41

Eigler A, Loher F, Endres S.
Suppression der Synthese des Tumornekrosefaktors.
Der Internist 2001; 1:28-34

Schulze J, Endres S.
Genotyp, Phänotyp und unerwünschte Arzneimittelreaktionen.
Arzneimitteltherapie 1999; 17:196-200

Hartmann G, Bidlingmaier M, Eigler A, Hacker UT, Endres S.
Cytokines as targets for therapeutic oligonucleotides.
Cytokines, Cellular and Molecular Therapy 1997; 3:247-56

Folwaczny C, Endres S..
Fischöl zur Rezidivprophylaxe bei M. Crohn?.
Zeitschrift für Gastroenterologie 1997; 35:651-3

Eigler A, Endres S.
Therapie mit Anti-TNF-αntikörper bei Patienten mit Morbus Crohn.
Zeitschrift für Gastroenterologie 1997; 35:899-901

Endres S, Eigler A.
Hemmung der NO-Synthase im septischen Schock.
Der Internist 1997; 38:466-9

Hartmann G, Krug A, Bidlingmaier M, Eigler A, Endres S.
Antisense strategies for inhibition of tumor necrosis factor-a synthesis.
Nucleosides and Nucleotides 1997; 629-34

Drenth JPH, Endres S, Belohradsky BH, van der Meer JWM.

Das Hyper-IgD-Syndrom.
Deutsche Medizinische Wochenschrift 1996; 121:1299-1300

Endres S, Sinha B, Eisenhut T.
n-3 Polyunsaturated fatty acids in the regulation of human cytokine synthesis.
Biochemical Society Transactions 1995; 23:277-81

Endres S, Sinha B, Eigler A.
Tumor-Nekrose-Faktor: Therapeutische Strategien zu Synthesehemmung und Antagonismus.
Deutsches Ärzteblatt 1995; 92:2185-8

Endres S.
Messengers and mediators: the interaction between lipids, eicosanoids and cytokines.
The American Journal of Clinical Nutrition 1993; 57:789-800

Markewitz A, Faist E, Weinhold C, Lang S, Endres S, Hültner L, Reichart B.
Alterations of cell-mediated immune response following cardiac surgery.
European Journal of Cardio-thoracic Surgery 1993; 105:15-24

Endres S, Hohnloser J.
Therapeutischer Einsatz von Zytokinen.
Münchner Medizinische Wochenschrift 1989; 131:507-9

Endres S.
Praktikum der Inneren Medizin in den USA.
Deutsche Medizinische Wochenschrift 1983; 108:1530-3